Clinical Trial Update: Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating durvalumab with or without tremelimumab versus standard-of-care chemotherapy in urothelial carcinoma; results were posted in May 2021 a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Urothelial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-05-13